"Artificial Intelligence + Medical Health" welcomes new policies, many listed companies are expected to benefit

On November 4th, the National Health Commission issued the "Implementation Opinions on Promoting and Regulating the Development of 'Artificial Intelligence + Medical Health'", specifying eight key application areas of "Artificial Intelligence + Medical Health", including artificial intelligence + grassroots application, artificial intelligence + clinical diagnosis and treatment, artificial intelligence + patient services, and artificial intelligence + traditional Chinese medicine. It also set development goals for the two stages of 2027 and 2030, delineating the development path for the artificial intelligence medical industry. It was noted that a number of A-share companies such as Shanwai Shan, Yunnan Baiyao, and Aojiawei have already laid out different industrial tracks in "Artificial Intelligence + Medical Health". The "Implementation Opinions" further specify the direction of industry support and key application areas, which will bring new opportunities for the business expansion of relevant listed companies and help them create new performance growth points.